Novo Nordisk A/S - Share repurchase programme On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 2 billion in the period from 31 January 2008 to 6 August 2008. Since the announcement as of 23 June 2008, the following transactions have been made under the programme: Number of Average Transaction shares purchase price value, DKK Accumulated, last 4,147,907 1,479,980,849 announcement 23 June 2008 45,000 303.3700 13,651,650 24 June 2008 45,000 311.0200 13,995,900 25 June 2008 45,000 314.4900 14,152,050 26 June 2008 45,000 319.8100 14,391,450 27 June 2008 45,000 316.3400 14,235,300 Accumulated, 2008 4,372,907 1,550,407,199 With the transactions stated above, Novo Nordisk owns a total of 16,526,430 treasury shares, corresponding to 2.6% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information: Media: Investors: Outside North America: Outside North America: Elin K Hansen Mads Veggerby Lausten Tel: (+45) 4442 3450 Tel: (+45) 4443 7919 ekh@novonordisk.com mlau@novonordisk.com Hans Rommer Tel: (+45) 4442 4765 hrmm@novonordisk.com In North America: In North America: Sean Clements Christian Qvist Frandsen Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com cqfr@novonordisk.com Stock Exchange Announcement no 41 /2008